Reduced Cortical Bone Mass in Mice with Inactivation of Interleukin-4 and Interleukin-13
2007 (English)In: Journal of Orthopaedic Research, ISSN 0736-0266, E-ISSN 1554-527X, Vol. 25, no 6, 725-731 p.Article in journal (Refereed) Published
The aim of the present study was to study the in vivo role of IL-4 and IL-13 on bone metabolism. The skeletal phenotypes of male and female IL-13-/- (n = 7+7), IL-4-/-IL-13-/- (n = 7+7), and WT (n = 7+7) mice were compared. Analysis was made at 6 weeks of age (juvenile) by pQCT, and at 20 weeks of age (adult) by pQCT, biomechanical testing, and by S-IGF-1 and S-Osteocalcin measurements. The skeletal phenotype was affected only in adult male IL-4-/-IL-13-/- mice. These animals displayed a reduction in cortical bone mineral content (BMC) of both the tibia and the femur, as measured by mid-diaphyseal pQCT scans, compared with WT mice (tibia -8.2%; femur -8.5%; p < 0.01). This reduction in cortical BMC was due to a decreased cross-sectional area as a result of a reduced cortical thickness. The mechanical strength of the cortical bone, tested by three-point-bending at the mid-diaphyseal region of the femurs, demonstrated a significant reduction of displacement at failure (-11.4%), maximal load at failure (-10.6%), and total energy until failure (-29.4%). S-IGF-1 and S-Osteocalcin levels as well as trabecular bone mineral density (tvBMD) were unaffected in adult male IL-4-/-IL-13-/- mice. IL-4-/-IL-13-/- male mice show adult onset reduction of cortical bone mass and strength, indicating that the two anti-inflammatory Th2 cytokines IL-4 and IL-13 are involved in the regulation of bone remodeling.
Place, publisher, year, edition, pages
2007. Vol. 25, no 6, 725-731 p.
bone, osteoblasts, interleukin-4, interleukin-13, transgenic
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-96656DOI: 10.1002/jor.20361ISI: 000246541300003PubMedID: 17318894OAI: oai:DiVA.org:uu-96656DiVA: diva2:171303